<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02961946</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002417</org_study_id>
    <nct_id>NCT02961946</nct_id>
  </id_info>
  <brief_title>Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality</brief_title>
  <official_title>Effects of Sublingual and Transdermal Administration of Nitroglycerin for Coronary CT Angiography on Image Quality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate image quality of coronary CT angiography (cCTA) after sublingual and transdermal
      administration of Nitroglycerin. Aim of this prospective research study is to investigate
      equivalence on image quality after sublingual or transdermal Nitroglycerin administration
      (H0).

      Furthermore, the feasibility of transdermal Nitroglycerin administration will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2017</start_date>
  <completion_date type="Actual">August 2, 2018</completion_date>
  <primary_completion_date type="Actual">October 31, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Coronary Artery Diameter Change</measure>
    <time_frame>obtained on the same day (day 0) of nitroglycerine administration (nitroglycerine is administered during the cCTA exam appointment).</time_frame>
    <description>Average diameter of coronary arteries at 7 predefined locations in the proximal, mid, and distal segments of the left main, left anterior descending, left circumflex and right coronary artery. Measurements avoid areas of coronary non-calcified and calcified plaques and measured twice for each location. Proximal and distal deviation from original measurements is possible in case of plaque.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Sublingual Nitroglycerin spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual Nitroglycerin spray of 0.8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sublingual Nitroglycerin tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sublingual Nitroglycerin tablet of 0.8 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitroglycerin skin patch</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nitroglycerin skin patch of 0.8 mg/h</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitroglycerin</intervention_name>
    <description>Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
    <arm_group_label>Nitroglycerin skin patch</arm_group_label>
    <arm_group_label>Sublingual Nitroglycerin spray</arm_group_label>
    <arm_group_label>Sublingual Nitroglycerin tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Scheduled cCTA with contrast.

          2. Able to comprehend and sign the consent form.

        Exclusion Criteria:

          1. Known hypersensitivity to glyceryl trinitrate, and related organic nitrates.

          2. Acute circulatory failure associated with marked hypotension (shock).

          3. Conditions associated with elevated intracranial pressure, cerebral haemorrhage and
             head trauma.

          4. Closed-angle glaucoma.

          5. Phosphodiesterase type 5 (PDE5) inhibitors such as sildenafil (ViagraÂ®), tadalafil
             (Cialis), or vardenafil (Levitra) within the last 24 hours

          6. Unstable clinical conditions (i.e. hemodynamic instability, arrhythmias)

          7. Critical aortic stenosis

          8. Systolic blood pressure &lt; 90 mmHg

          9. Pregnant or lactating female; premenopausal women with a positive urine pregnancy
             test.

         10. Age under 18

         11. Unwilling or unable to inform consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 3, 2016</study_first_submitted>
  <study_first_submitted_qc>November 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 11, 2016</study_first_posted>
  <results_first_submitted>August 3, 2019</results_first_submitted>
  <results_first_submitted_qc>August 28, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 17, 2019</results_first_posted>
  <last_update_submitted>August 28, 2019</last_update_submitted>
  <last_update_submitted_qc>August 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Brian Ghoshhajra</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02961946/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT02961946/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sublingual Nitroglycerin Spray</title>
          <description>Sublingual Nitroglycerin spray of 0.8 mg
Nitroglycerin: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
        </group>
        <group group_id="P2">
          <title>Sublingual Nitroglycerin Tablet</title>
          <description>Sublingual Nitroglycerin tablet of 0.8 mg
Nitroglycerin: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
        </group>
        <group group_id="P3">
          <title>Nitroglycerin Skin Patch</title>
          <description>Nitroglycerin skin patch of 0.8 mg/h
Nitroglycerin: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="66"/>
                <participants group_id="P3" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sublingual Nitroglycerin Spray</title>
          <description>Sublingual Nitroglycerin spray of 0.8 mg
Nitroglycerin: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
        </group>
        <group group_id="B2">
          <title>Sublingual Nitroglycerin Tablet</title>
          <description>Sublingual Nitroglycerin tablet of 0.8 mg
Nitroglycerin: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
        </group>
        <group group_id="B3">
          <title>Nitroglycerin Skin Patch</title>
          <description>Nitroglycerin skin patch of 0.8 mg/h
Nitroglycerin: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="66"/>
            <count group_id="B2" value="66"/>
            <count group_id="B3" value="66"/>
            <count group_id="B4" value="198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="66"/>
                    <count group_id="B4" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59" spread="13"/>
                    <measurement group_id="B2" value="58" spread="13"/>
                    <measurement group_id="B3" value="57" spread="12"/>
                    <measurement group_id="B4" value="58" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="66"/>
                    <count group_id="B4" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary diameter</title>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="66"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="66"/>
                    <count group_id="B4" value="198"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.3" spread="0.9"/>
                    <measurement group_id="B2" value="3.5" spread="1.0"/>
                    <measurement group_id="B3" value="3.4" spread="1.0"/>
                    <measurement group_id="B4" value="3.4" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Coronary Artery Diameter Change</title>
        <description>Average diameter of coronary arteries at 7 predefined locations in the proximal, mid, and distal segments of the left main, left anterior descending, left circumflex and right coronary artery. Measurements avoid areas of coronary non-calcified and calcified plaques and measured twice for each location. Proximal and distal deviation from original measurements is possible in case of plaque.</description>
        <time_frame>obtained on the same day (day 0) of nitroglycerine administration (nitroglycerine is administered during the cCTA exam appointment).</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sublingual Nitroglycerin Spray</title>
            <description>Sublingual Nitroglycerin spray of 0.8 mg
Nitroglycerin: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
          </group>
          <group group_id="O2">
            <title>Sublingual Nitroglycerin Tablet</title>
            <description>Sublingual Nitroglycerin tablet of 0.8 mg
Nitroglycerin: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
          </group>
          <group group_id="O3">
            <title>Nitroglycerin Skin Patch</title>
            <description>Nitroglycerin skin patch of 0.8 mg/h
Nitroglycerin: Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Coronary Artery Diameter Change</title>
          <description>Average diameter of coronary arteries at 7 predefined locations in the proximal, mid, and distal segments of the left main, left anterior descending, left circumflex and right coronary artery. Measurements avoid areas of coronary non-calcified and calcified plaques and measured twice for each location. Proximal and distal deviation from original measurements is possible in case of plaque.</description>
          <units>Fold change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" lower_limit="1.12" upper_limit="1.15"/>
                    <measurement group_id="O2" value="1.13" lower_limit="1.09" upper_limit="1.16"/>
                    <measurement group_id="O3" value="1.15" lower_limit="1.13" upper_limit="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From time of nitroglycerin was given until until patients left the Radiology department. Usually 1 hour after the exam.</time_frame>
      <desc>There were no patients with serious adverse events. There were no patients with all-cause mortality. There were no patients with other adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sublingual Nitroglycerin Spray</title>
          <description>Sublingual Nitroglycerin spray of 0.8 mg
Patients will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan.</description>
        </group>
        <group group_id="E2">
          <title>Sublingual Nitroglycerin Tablet</title>
          <description>Sublingual Nitroglycerin tablet of 0.8 mg
Patients will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan.</description>
        </group>
        <group group_id="E3">
          <title>Nitroglycerin Skin Patch</title>
          <description>Nitroglycerin skin patch of 0.8 mg/h
Patients categorized to transdermal administration will receive Nitroglycerin after Calcium scoring scan and 1 hour before the cCTA examination. The patch will be placed on the chest or the upper arm.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="66"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>To evaluate coronary diameter change by nitroglycerin administration, non-constrast and contrast ECG-gated images were compared. Measurements avoided areas of visible arteriosclerosis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Brian Ghoshhajra</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-726-5954</phone>
      <email>BGHOSHHAJRA@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

